Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Delayed Effects Plus Dose Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

NCT04722601
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Obinutuzumab, CC-486
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 4, 2026, 5:05 AM EDT
Terminated Not applicable Interventional Results available

Ketorolac Effects on Post-operative Pain and Bone Healing

NCT01133639
View directory record Official record
Conditions
Bunion
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double-Blind Randomized Controlled Trial for the Evaluation of a Novel Adaptive Attention Training in Healthy Adolescents

NCT03213613
View directory record Official record
Conditions
Healthy Adolescents
Interventions
Adaptive Attention Training, Active Control, Low-dose Adaptive Attention Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

NCT01718938
View directory record Official record
Conditions
Gastroparesis
Interventions
velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Los Angeles, California • Ventura, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 4, 2026, 5:05 AM EDT
Active, not recruiting Phase 4 Interventional

Long-term Effectiveness of the Antiobesity Medication Phentermine

NCT05176626
View directory record Official record
Conditions
Obesity, Obesity; Drug, Lifestyle, Healthy
Interventions
Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Active, not recruiting Not applicable Interventional

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

NCT05568264
View directory record Official record
Conditions
Motor Delay, Premature Birth, Intraventricular Hemorrhage, Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia
Interventions
Physical Therapy intervention
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
33 Weeks to 48 Weeks
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Depression Interventions After Acute Coronary Syndrome

NCT01032018
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
Behavioral · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

NCT02221219
View directory record Official record
Conditions
Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Renal Injury
Interventions
Indomethacin, delay in umbilical cord clamp at birth, placebo infusion, immediate cord clamp at birth
Drug · Procedure
Lead sponsor
Hong Huang
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 4, 2026, 5:05 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Stimulant Effects on Disruptive Behavior

NCT03420339
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions
Stimulant
Drug
Lead sponsor
Matthew J O'Brien, PhD, BCBA-D
Other
Eligibility
48 Months to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 4 Interventional Results available

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

NCT03064035
View directory record Official record
Conditions
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions
4-factor prothrombin complex concentrate (4FPCC)
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 125 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

NCT03585270
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Effect of High Doses of Radiation on Bone Structure and Metabolism

NCT02323295
View directory record Official record
Conditions
Malignant Bone Tumors
Interventions
Radiation (Surgical Arm), Radiation (Non-surgical Arm), Malignant Tumor Surgery
Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

NCT02526524
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Met DR, Met IR, Placebo
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
134
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 4, 2026, 5:05 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence

NCT02543723
View directory record Official record
Conditions
Medication Adherence
Interventions
Nurse Coach Intervention
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 4, 2026, 5:05 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

NCT05730205
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Nexplanon 68 MG Drug Implant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

NCT01844583
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Alisertib, Esomeprazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 4, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

NCT06206265
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

NCT00974051
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Terbutaline, 20% basal insulin reduction, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Sep 4, 2026, 5:05 AM EDT